This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
by Zacks Equity Research
The FDA approves label expansion of Regeneron (REGN) and Sanofi's Kevzara for the treatment of polyarticular juvenile idiopathic arthritis.
REGNPositive Net Change SNYNegative Net Change NERVPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Are Options Traders Betting On a Big Move In Align Technology (ALGN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Align Technology (ALGN) stock based on the movements in the options market lately.
ALGNNegative Net Change
medical
Humana's (HUM) CenterWell Sets Foot in Asheville With New Centers
by Zacks Equity Research
Humana's (HUM) CenterWell Senior Primary Care announces the opening of two centers in Asheville, thus enhancing access to high-quality healthcare services and driving revenues of the CenterWell unit.
HUMPositive Net Change LMATNo Net Change LNTHPositive Net Change ELANPositive Net Change
medical
Brookdale (BKD) Sees 31 Months of Y/Y Occupancy Growth Streak
by Zacks Equity Research
Brookdale's (BKD) weighted average occupancy for the second quarter-to-date rises 160 bps year over year to 78%.
BKDPositive Net Change HQYNegative Net Change SERAPositive Net Change AURANegative Net Change
medical
Surmodics (SRDX) Inks Group Purchasing Agreement With Premier
by Zacks Equity Research
Surmodics (SRDX) inks the group purchasing agreement for its thrombectomy products with Premier.
BSXNegative Net Change ECLPositive Net Change DVANegative Net Change SRDXNegative Net Change
medical medical-devices
Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination vaccine generates higher immune responses when compared to co-administered licensed flu and COVID vaccines.
PFENegative Net Change MRNANegative Net Change NVAXPositive Net Change BNTXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
by Zacks Equity Research
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
CGENNo Net Change APLSPositive Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes
by Zacks Equity Research
Myriad Genetics (MYGN) continues to enhance its customer targeting, digital marketing and overall operating model to drive commercial leverage in 2024 and beyond.
RMDNegative Net Change MYGNPositive Net Change MEDPNegative Net Change HIMSPositive Net Change
medical medical-devices
Charles River (CRL) Partners to Reduce Animal Research Usage
by Zacks Equity Research
Charles River (CRL) announces the development of non-clinical VCG with Sanofi to reduce the use of animals in research.
RMDNegative Net Change CRLNegative Net Change MEDPNegative Net Change HIMSPositive Net Change
medical medical-devices
Here's Why You Should Hold McKesson (MCK) in Your Portfolio Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
BSXNegative Net Change ECLPositive Net Change DVANegative Net Change MCKNo Net Change
medical medical-devices
Zacks.com featured highlights include ResMed, Booz Allen Hamilton, CrediCorp and American Express
by Zacks Equity Research
ResMed, Booz Allen Hamilton, CrediCorp and American Express have been highlighted in this Screen of The Week article.
AXPNegative Net Change RMDNegative Net Change BAHNegative Net Change BAPNegative Net Change
finance medical
The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Verizon, Taylor Devices and Frequency Electronics
by Zacks Equity Research
Broadcom, Johnson & Johnson, Verizon, Taylor Devices and Frequency Electronics are included in this Analyst Blog.
JNJNegative Net Change VZPositive Net Change AVGOPositive Net Change FEIMPositive Net Change TAYDPositive Net Change
computers medical
Apple Joins A.I. Race; Lilly Thumbs-Up on Alzheimer's Drug
by Mark Vickery
Considering how many Apple products there are out there in the world at this time, a high number of them will soon be accessing A.I. from an Apple device.
BIIBNegative Net Change AAPLPositive Net Change LLYPositive Net Change
artificial-intelligence communications medical pharmaceuticals tech-stocks
Select Medical (SEM) Rises 42.4% YTD: More Growth Ahead?
by Zacks Equity Research
Select Medical (SEM) will continue to gain from rising admissions within the Critical Illness Recovery Hospital and Rehabilitation Hospital segments.
BKDPositive Net Change SEMNegative Net Change HQYNegative Net Change SERAPositive Net Change
medical
Will UnitedHealth (UNH) Dividend Hike Fail to Excite Investors?
by Zacks Equity Research
UnitedHealth's (UNH) strong financial position supports its shareholder value boosting efforts.
UNHPositive Net Change BKDPositive Net Change HQYNegative Net Change SERAPositive Net Change
medical
Veeva Systems' (VEEV) Vault EDC to Boost Tigermed's Workflow
by Zacks Equity Research
Veeva Systems' (VEEV) Vault EDC is likely to streamline key processes to accelerate study builds and make mid-study amendments with no downtime.
BSXNegative Net Change ECLPositive Net Change DVANegative Net Change VEEVPositive Net Change
medical medical-devices
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
by Zacks Equity Research
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
BMYPositive Net Change GERNPositive Net Change KRYSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion
by Zacks Equity Research
Roche's (RHHBY) Alecensa gets the European Commission's approval as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer.
RHHBYPositive Net Change NERVPositive Net Change KRYSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
DaVita (DVA), Nuwellis Extend Pilot Collaboration for Aquadex
by Zacks Equity Research
DaVita (DVA) extends its pilot collaboration with Nuwellis to conduct additional testing of the Aquadex ultrafiltration treatment for adult patients suffering from congestive heart failure and related conditions.
BSXNegative Net Change ECLPositive Net Change DVANegative Net Change ALGNNegative Net Change
medical medical-devices
Align Technology (ALGN) Gains From New Alliances, Global Growth
by Zacks Equity Research
Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America.
ALGNNegative Net Change RMDNegative Net Change MEDPNegative Net Change HIMSPositive Net Change
medical
4 GARP Stocks to Scoop up for Maximum Returns
by Shilpa Mete
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RMD, BAH, BAP and AXP are some stocks that hold promise.
AXPNegative Net Change RMDNegative Net Change BAHNegative Net Change BAPNegative Net Change
business-services finance medical
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
by Zacks Equity Research
ChromaDex (CDXC) rises 12% as the FDA grants the Orphan Drug Designation and the Rare Pediatric Disease Designation to its investigational candidate, NRC, to treat ataxia telangiectasia.
CGENNo Net Change CDXCNo Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review
by Zacks Equity Research
Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.
PFENegative Net Change MRNANegative Net Change NVAXPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Capricor (CAPR) Advances in DMD Therapy With Positive Study Data
by Zacks Equity Research
Capricor (CAPR) anticipates announcing top-line results from the Phase 3 HOPE-3 pivotal trial by the fourth quarter of 2024.
RMDNegative Net Change CAPRPositive Net Change MEDPNegative Net Change HIMSPositive Net Change
medical
QIAGEN (QGEN) Unveils dPCR Tool, Enhances GeneGlobe Platform
by Zacks Equity Research
QIAGEN (QGEN) launches the digital PCR Assay Design Tool for QIAcuity and expands the customization capabilities of its GeneGlobe research platform.
RMDNegative Net Change QGENNegative Net Change MEDPNegative Net Change HIMSPositive Net Change
medical medical-devices